Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's $187.5 mil. purchase of Richwood will bring U.S. marketing presence.

Executive Summary

SHIRE TO GAIN U.S. MARKETING ARM THROUGH $185.7 MIL. RICHWOOD PURCHASE if the deal is approved by Shire shareholders Aug. 20, Hampshire, England-based Shire Pharmaceuticals said. The company announced Aug. 4 the proposed acquisition of Florence, Ky.-based Richwood Pharmaceuticals for $145.8 mil. in stock (31% of Shire's equity), $15 mil. in cash, and 7.2 mil. options valued at $24.9 mil. Richwood will be Shire's second acquisition this year: the company acquired the Gaithersburg, Md.-based drug delivery company Pharmavene in February for $90.5 mil.

You may also be interested in...



FDA Warning Letter To Xanodyne Cites Risk Info Omissions In Brochure

An FDA warning letter to Xanodyne Pharmacal cites a lack of product risk information in a corporate brochure

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS030670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel